Core Insights - The article expresses measured optimism regarding Coherus Oncology, Inc. following their sale of a pegfilgrastim version, indicating potential investment opportunities in the biotech sector [1]. Company Summary - Coherus Oncology, Inc. is involved in the sale of pegfilgrastim, a drug used to reduce the risk of infection in patients undergoing chemotherapy [1]. Industry Context - The article highlights the importance of understanding the science behind biotech investments, emphasizing the need for thorough due diligence to avoid pitfalls in the industry [1].